Physician profile
Sameer Bahl
NPI 1639674260
$1,726.94
in general payments reported to CMS, 2019-2025
12 companies · $438 in 2025
The $438 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $222 · 2023: $487 · 2024: $580 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,424 · Education: $80.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,423.75 |
| Education | $80.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $350.01 | 2023-2024 | Impella |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $251.22 | 2022-2024 | Lifevest |
| Angiodynamics, INC. | $209.91 | 2025 | Angiovac |
| Astrazeneca Pharmaceuticals LP | $184.72 | 2025 | |
| Medtronic, INC. | $161.61 | 2024 | Corevalve Evolut R |
| Janssen Pharmaceuticals, INC | $124.99 | 2024 | Xarelto |
| Chiesi USA, INC. | $121.72 | 2022 | |
| Boston Scientific Corporation | $115.29 | 2024 | Opticross |
| Merck Sharp & Dohme LLC | $73.63 | 2023-2025 | Verquvo |
| Lantheus Medical Imaging, INC. | $60.27 | 2022-2024 | |
| E.R. Squibb & Sons, L.L.C. | $48.18 | 2022-2023 | Camzyos |
| Alnylam Pharmaceuticals INC. | $25.39 | 2023 | Amvuttra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sameer Bahl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.